S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
NASDAQ:SPRO

Spero Therapeutics - SPRO Competitors

$2.10
+0.10 (+5.00%)
(As of 10/5/2022 05:29 PM ET)
Add
Compare
Today's Range
$2.01
$2.24
50-Day Range
$0.68
$2.20
52-Week Range
$0.68
$18.71
Volume
4.65 million shs
Average Volume
2.83 million shs
Market Capitalization
$73.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33

SPRO vs. BIVI, EYEN, TRVI, RPHM, GNPX, ONCY, LUMO, SCYX, EQ, and FREQ

Should you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include BioVie (BIVI), Eyenovia (EYEN), Trevi Therapeutics (TRVI), Reneo Pharmaceuticals (RPHM), Genprex (GNPX), Oncolytics Biotech (ONCY), Lumos Pharma (LUMO), SCYNEXIS (SCYX), Equillium (EQ), and Frequency Therapeutics (FREQ). These companies are all part of the "pharmaceutical preparations" industry.

Spero Therapeutics vs.

Spero Therapeutics (NASDAQ:SPRO) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability, dividends and community ranking.

Spero Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, BioVie has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500.

In the previous week, BioVie had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 4 mentions for BioVie and 3 mentions for Spero Therapeutics. BioVie's average media sentiment score of 0.74 beat Spero Therapeutics' score of 0.73 indicating that BioVie is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Spero Therapeutics
0 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioVie
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

57.4% of Spero Therapeutics shares are held by institutional investors. Comparatively, 6.6% of BioVie shares are held by institutional investors. 4.4% of Spero Therapeutics shares are held by insiders. Comparatively, 83.6% of BioVie shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BioVie has a net margin of 0.00% compared to Spero Therapeutics' net margin of -1,147.64%. Spero Therapeutics' return on equity of -151.75% beat BioVie's return on equity.

Company Net Margins Return on Equity Return on Assets
Spero Therapeutics -1,147.64% -151.75% -86.27%
BioVie N/A -208.99% -104.18%

Spero Therapeutics received 180 more outperform votes than BioVie when rated by MarketBeat users. Likewise, 68.57% of users gave Spero Therapeutics an outperform vote while only 63.16% of users gave BioVie an outperform vote.

CompanyUnderperformOutperform
Spero TherapeuticsOutperform Votes
192
68.57%
Underperform Votes
88
31.43%
BioVieOutperform Votes
12
63.16%
Underperform Votes
7
36.84%

Spero Therapeutics currently has a consensus target price of $6.33, suggesting a potential upside of 203.03%. BioVie has a consensus target price of $10.50, suggesting a potential upside of 303.85%. Given BioVie's stronger consensus rating and higher probable upside, analysts clearly believe BioVie is more favorable than Spero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spero Therapeutics
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
BioVie
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

BioVie has lower revenue, but higher earnings than Spero Therapeutics. Spero Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spero Therapeutics$18.26 million4.01-$89.76 million-$3.48-0.60
BioVieN/AN/A-$26.08 million-$10.91-0.24

Summary

BioVie beats Spero Therapeutics on 10 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRO vs. The Competition

MetricSpero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$73.30M$5.38B$4.22B$5.43B
Dividend YieldN/A2.67%7.97%4.22%
P/E Ratio-0.6012.3593.7313.16
Price / Sales4.01425.413,216.37101.84
Price / CashN/A21.5623.4980.71
Price / Book0.777.895.875.60
Net Income-$89.76M$183.76M$163.07M$236.82M
7 Day Performance1.95%1.49%2.00%2.07%
1 Month Performance186.30%-6.69%-6.24%-5.33%
1 Year Performance-88.87%-41.63%-34.45%-29.76%

Spero Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIVI
BioVie
1.9511 of 5 stars
$2.56
+8.5%
$10.50
+310.2%
-59.5%$73.27MN/A-0.236Positive News
Gap Up
EYEN
Eyenovia
2.1801 of 5 stars
$2.06
+8.4%
$9.00
+336.9%
-58.5%$70.48M$14M-3.6143Analyst Report
News Coverage
Gap Up
TRVI
Trevi Therapeutics
2.2279 of 5 stars
$1.72
-1.7%
$10.67
+520.2%
+36.5%$73.57MN/A-1.7224Analyst Revision
Gap Up
RPHM
Reneo Pharmaceuticals
2.4065 of 5 stars
$3.01
-2.9%
$28.80
+856.8%
-49.7%$73.69MN/A-1.5224
GNPX
Genprex
1.748 of 5 stars
$1.45
+2.1%
N/A-45.1%$69.63MN/A-3.4512Short Interest ↓
News Coverage
Positive News
Gap Up
ONCY
Oncolytics Biotech
2.1898 of 5 stars
$1.29
+1.6%
$6.00
+365.1%
-31.2%$74.86MN/A-3.7926Positive News
LUMO
Lumos Pharma
2.1227 of 5 stars
$8.93
-0.8%
$24.00
+168.8%
-4.4%$74.98M$230,000.00-2.6029
SCYX
SCYNEXIS
2.1486 of 5 stars
$2.33
+1.3%
$8.00
+243.3%
-49.2%$76.08M$13.16M-1.4638
EQ
Equillium
1.878 of 5 stars
$2.23
-5.9%
$13.00
+483.0%
-68.4%$76.44MN/A-0.9745High Trading Volume
FREQ
Frequency Therapeutics
2.4283 of 5 stars
$1.90
+3.8%
$10.00
+426.3%
-72.5%$67.00M$14.07M-0.7272Positive News
Gap Up
This page (NASDAQ:SPRO) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.